Having received a large number of Letters of intent (LOIs) of a high standard we are very pleased to announce that we have made the first step in the selection process.
The following six applications have been selected for a site visit.
- Ivory Coast
- Sri Lanka
All complete, eligible applications were reviewed by an independent, external panel of experts with experience in leading large trials and reviewing applications for large funding agencies.
The panel was comprised of the following members:
Chair: Professor Jimmy Whitworth (London School of Hygiene and Tropical Medicine)
- Professor Dan Colley (University of Georgia)
- Professor John Gyapong (University of Ghana)
- Dr. Harriet Mpairwe (Medical Research Council Uganda/Uganda Virus Research Institute)
- Professor Ric Price (Menzies School of Health Research/ University of Oxford)
(Please note: these individuals should not be contacted directly regarding the review process; all communication should go through Dr Judd Walson.)
The site visits will be an opportunity for the DeWorm3 project team to meet with the shortlisted group of applicants and their partners to discuss the roles and responsibilities of the sites and to further assess the applicants’ abilities to conduct large field trials.
If your site is shortlisted and selected for a visit, the Natural History Museum will provide a small amount of funding to cover costs associated with hosting the visit.
We expect these site visits to occur in May or June of 2016.
Research partners will be announced in June 2016.
If you have any further questions please contact the DeWorm3 team.
We will test the feasibility of eliminating soil-transmitted helminths (STHs, or intestinal worms) and developing cost-effective methods for scaling up elimination programs.
Over 1.45 billion people are infected with soil-transmitted helminths (STHs), including 845 million children, in some of the world’s poorest communities.
The project will be led by a team at the Natural History Museum in London and will last for five-years, in the first instance. Museum scientists have a long history of researching disease and understanding the identity, nature and diversification of parasites and vectors.
The DeWorm3 project aims to
- demonstrate the feasibility of eliminating STHs using existing and intensified mass drug administration (MDA) strategies, specifically by leveraging existing lymphatic filariasis elimination platforms
- inform the guidelines, policies, and operational plans needed to successfully achieve STH elimination
- link qualitative and operational studies of the acceptability and feasibility of different strategies to ongoing field trials, guiding future implementation and scale-up plans.
STHs reduce the body’s ability to absorb nutrients and vitamins. This can exacerbat malnutrition and lead to anaemia, increased susceptibility to other infectious diseases, stunted growth and impaired cognitive development.
STHs are a group of intestinal parasites that thrive in areas with warm, humid soil and poor sanitation. The most common STH parasites are nematodes, including roundworm (Ascaris), whipworm (Trichuris), and hookworm (Ancylostoma and Necator).
STHs are controlled primarily through school-based mass drug administration (MDA) programmes where albendazole or mebendazole are given to children.
However, recent studies suggest that successfully interrupting the transmission of STHs may require broadening treatment to pre-school-age children and adults through community-based MDA platforms.
In addition, alternative combinations or delivery schedules of antihelminthic drugs may be required to break transmission of these diseases.
STHs share a co-indicated drug (albendazole) and are geographically congruent with other neglected tropical diseases (NTDs), including lymphatic filariasis. This creates the potential for a coordinated elimination approach.
However, strategies to inform guidelines in countries transitioning from disease control to elimination in an integrated fashion have not been fully evaluated.
- Conduct field trials to assess optimal strategies for interrupting disease transmission and reducing morbidity.
- Develop implementation strategies to achieve successful STHs elimination at scale.
- Develop clear definitions (epidemiologic and operational) of STHs transmission interruption.